Patent US5000956A successfully refreshed from Google Patents.
US5000956A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
Assignee: Alza Corp
•
Filing: 1988-07-08
•
Granted: 1991-03-19
•
Expires: 2008-07-08
Abstract
Abstract A method of preventing sensitization in transdermal drug delivery by the inclusion of a corticosteroid, which wll be co-extensively coadministered with the sensitizing agent.
Inventors
- 👤 Alfred Amkraut
- 👤 Jane E. Shaw
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 20:42
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084; A61K31/00; A61K31/56; A61K31/57
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
170 words
A method of reducing induction of sensitization of human mucosa during transmucosal administration of a drug to a human, which drug is susceptible to inducing mucosal sensitization in the human when the drug is transmucosally administered at a therapeutically effective rate, comprising: (a) continuously and co-extensively administering to a selected site on the human mucosa; (1) the drug, at a therapeutically effective rate over a predetermined delivery period; and (2) a corticosteroid, (i) at a rate within the range range of about 0.01 to 5 μg/cm 2 -hr which is capable of inhibiting the induction of sensitization and (ii) during the entire delivery period when the drug is transmucosally administered, both the drug and the corticosteroid being administered from a matrix or carrier placed in drug and corticosteroid transmitting relationship to the mucosa; (b) discontinuing the administration of the drug to the selected site following the predetermined delivery period; and (c) continuously and co-extensively readministering the drug and the corticosteroid to a different site on the mucosa of the human.
Claim 2
Independent Claim
170 words
A method of reducing induction of sensitization of human mucosa during transmucosal administration of a drug to a human, which drug is susceptible to inducing mucosal sensitization in the human when the drug is transmucosally administered at a therapeutically effective rate, comprising: (a) continuously and co-extensively administering to a selected site on the human mucosa; (1) the drug, at a therapeutically effective rate over a predetermined delivery period; and (2) a corticosteroid, (i) at a rate within the range range of about 0.01 to 5 μg/cm 2 -hr which is capable of inhibiting the induction of sensitization and (ii) during the entire delivery period when the drug is transmucosally administered, both the drug and the corticosteroid being administered from a matrix or carrier placed in drug and corticosteroid transmitting relationship to the mucosa; (b) discontinuing the administration of the drug to the selected site following the predetermined delivery period; and (c) continuously and co-extensively readministering the drug and the corticosteroid to a different site on the mucosa of the human.
Claim 3
Dependent Claim
10 words
The method of claim 1, including administering to mucosa site.
Claim 4
Dependent Claim
37 words
The method of claim 1, wherein said corticosteroid is selected from the group consisting of hydrocortisone, hydrocortisone acetate, hydrocortisone esters, beclomethasone, betamethasone, benzoid, betamethasone dipropionate, betamethasone valcrate, clobetasol propionate, clobetasol butyrate, desonide, dexamethasone, fluocinonide, prednisolone and triamcinolone.
Claim 5
Dependent Claim
30 words
The method of claim 1, including transmucosally administering to the selected mucosa site a permeation enhancer which is effective to enhance the rate at which the corticosteroid is transmucosally administered.
Claim 6
Dependent Claim
27 words
The method of claim 1, wherein said drug is selected from the group consisting of clonidine, scopolamine, tetracaine, chlorpheniramine maleate, naloxone, naltrexone, nalbuphine, levorphanol, hydromorphone and buprenorphine.
Claim 7
Dependent Claim
25 words
The method of claim 1, wherein the drug is administered to the selected site at a constant drug delivery rate over the predetermined delivery period.
Claim 8
Dependent Claim
19 words
The method of claim 3, wherein the corticosteroid is selected from the group consisting of hydrocortisone and hydrocortisone esters.
Claim 9
Dependent Claim
22 words
The method of claim 4, wherein the permeation enhancer is selected from the group consisting of oily surfactants, alcohols and keratinolytic agents.
Claim 10
Dependent Claim
24 words
The method of claim 8, wherein the permeation enhancer comprises an oily surfactant selected from the group consisting of sucrose monolaurate and glycerol monooleate.
Claim 11
Dependent Claim
18 words
The method of claim 1, wherein the drug and the corticosteroid are administered from an aqueous based formulation.
Claim 12
Dependent Claim
23 words
The method of claim 10, wherein the aqueous based formulation contains a gelling agent selected from the group consisting of hydroxyethylcellulose and hydroxypropylcellulose.
Claim 13
Dependent Claim
32 words
The method of claim 1, wherein the drug and the corticosteroid are administered from a non-aqueous based formulation containing a liquid selected from the group consisting of silicone fluid and mineral oil.
Claim 14
Dependent Claim
19 words
The method of claim 12, wherein the non-aqueous based formulation contains a gelling agent comprised of colloidal silicon dioxide.
References Cited (Backward Citations)
US3598122A
Cited
US3598122B1
Cited
US3598123A
Cited
US4144317A
Cited
US4130643A
Cited
EP0040861A1
Cited
US4292303A
Cited
US4286592A
Cited
US4314557A
Cited
US4379454A
Cited
US4362737A
Cited
US4353896A
Cited
US4343798A
Cited
US4608249A
Cited
US4559222A
Cited
US4548922A
Cited
JPS6023312A
Cited
US4634766A
Cited
EP0159168A2
Cited
US4573995A
Cited
EP0196769A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-03-18 | 1994-09-17 | 1995-03-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-03-18 | 1998-09-17 | 1999-03-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-03-18 | 2002-09-17 | 2003-03-19 | $7700.00 | Window Closed / Lapsed |